Novozymes A/S (OTCMKTS:NVZMY) Stock Short Interest Drops 64.7%

Novozymes A/S (OTCMKTS:NVZMY) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 12,081 shares, a decrease of 64.7% from the August 31st total of 34,196 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 39,198 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Novozymes A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Novozymes A/S has an average rating of “Buy”.

Novozymes A/S Trading Down 3.6%

Shares of NVZMY stock traded down $2.41 during trading hours on Friday, hitting $65.02. The company had a trading volume of 23,418 shares, compared to its average volume of 21,917. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.74 and a quick ratio of 1.03. The stock has a market capitalization of $26.95 billion, a PE ratio of 41.15, a price-to-earnings-growth ratio of 2.82 and a beta of 0.93. The company’s fifty day moving average is $66.63 and its 200 day moving average is $62.07. Novozymes A/S has a fifty-two week low of $49.90 and a fifty-two week high of $75.27.

Novozymes A/S (OTCMKTS:NVZMY) last posted its earnings results on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.16). Novozymes A/S had a net margin of 14.70% and a return on equity of 6.54%. The company had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.27 billion. Research analysts expect that Novozymes A/S will post 2.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Novozymes A/S

An institutional investor recently raised its stake in Novozymes A/S stock. Elefante Mark B increased its position in shares of Novozymes A/S (OTCMKTS:NVZMY) by 73.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,900 shares of the biotechnology company’s stock after acquiring an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Novozymes A/S

Novozymes A/S was a Danish biotechnology company that developed and commercialized enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its technologies were designed to help customers improve production efficiency, reduce resource use and develop more sustainable products and processes.

The company supplied biological products and related solutions to a range of industries, including food and beverages, household care, agriculture, animal health, bioenergy and industrial manufacturing.